Genetics and a dig at rivals for the holidays

Share this article:

23andMe's crisis is DNA Spectrum's gain. The rival genetic testing service released an announcement Tuesday, saying that while 23andMe has angered the FDA by promoting product claims it cannot support, the Phoenix, AZ, company “continues to be committed to the protection of consumers in genetic testing.”

DNA Spectrum's announcement notes the company has a “cutting-edge lineup of genetic ancestry services,” and that it is ready to provide “the best personal genetics holiday gifts to share with family and friends.”

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

The Women's Health landscape is ripe with opportunity for pharma marketers. This seven-page eBook offers product managers a guide to capitalizing on the trends, growth areas and unmet needs. Includes alternative channels to engage OB/GYNs and oncologists, and plenty of tips. Click here to access it.

Email Newsletters